Antimicrobial Agents and Chemotherapy · 2015 · 128 citations · 24 references
Life SciencesInfectious DiseasesMicrobiologyAntimicrobial ResistanceMedical MicrobiologyMycologyAntibiotic ResistanceAntifungal ResistanceAntifungal TherapyAntimicrobial Susceptibility TestingFungal InfectionsResistance EpidemiologyAntifungal ChemotherapyAntifungal Drug ResistanceAntifungal Susceptibility TestingFungal Drug ResistanceFungal Pathogen DetectionItraconazole TherapyResistance Breakpoint DeterminationResistance In Clinical Isolates
Clinical breakpoints (CBPs) have not been established for the Mucorales and any antifungal agent. In lieu of CBPs, epidemiologic cutoff values (ECVs) are proposed for amphotericin B, posaconazole, and itraconazole and four Mucorales species. Wild-type (WT) MIC distributions (organisms in a species-drug combination with no detectable acquired resistance mechanisms) were defined with available pooled CLSI MICs from 14 laboratories (Argentina, Australia, Canada, Europe, India, Mexico, and the United States) as follows: 10 Apophysomyces variabilis, 32 Cunninghamella bertholletiae, 136 Lichtheimia corymbifera, 10 Mucor indicus, 123 M. circinelloides, 19 M. ramosissimus, 349 Rhizopus arrhizus, 146 R. microsporus, 33 Rhizomucor pusillus, and 36 Syncephalastrum racemosum isolates. CLSI broth microdilution MICs were aggregated for the analyses. ECVs comprising ≥95% and ≥97.5% of the modeled populations were as follows: amphotericin B ECVs for L. corymbifera were 1 and 2 μg/ml, those for M. circinelloides were 1 and 2 μg/ml, those for R. arrhizus were 2 and 4 μg/ml, and those for R. microsporus were 2 and 2 μg/ml, respectively; posaconazole ECVs for L. corymbifera were 1 and 2, those for M. circinelloides were 4 and 4, those for R. arrhizus were 1 and 2, and those for R. microsporus were 1 and 2, respectively; both itraconazole ECVs for R. arrhizus were 2 μg/ml. ECVs may aid in detecting emerging resistance or isolates with reduced susceptibility (non-WT MICs) to the agents evaluated.
24
Anna Skiada, Livio Pagano, Andreas H. Groll et al. · Clinical Microbiology and Infection · 2011 · 746 citations · Full text
Amphotericin B: Time for a New "Gold Standard"
Louis D. Saravolatz, Luis Ostrosky‐Zeichner, Kieren A. Marr et al. · Clinical Infectious Diseases · 2003 · 406 citations